Literature DB >> 6896279

In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing.

D Brockmeier, H M von Hattingberg.   

Abstract

The profile of cumulative amount released from a solid dosage form, observed in an in vitro liberation apparatus, represents the cumulative frequency of the residence times of drug molecules in the galenic formulation. The profile of release over time is usually affected by the dissolution models as well as by the experimental conditions. Such differing dissolution curves may become superimposable by a simple linear transformation of the time base. This is clearly demonstrated by two completely different retard formulations, film coated pellets and an erosible matrix tablet, which were tested in two dissolution apparatus, the Sartorius dissolution model and the USP-Paddle model. The parameters used in the transformation of the time base can be evaluated from the statistical moments of the residence times; the moments themselves are calculated from the cumulative frequency functions. The term "equivalence" of dissolution profiles is defined and discussed. The outlined considerations and methods are immediately transferable to the comparison of in vitro and in vivo liberation conditions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6896279

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  The description of the gastrointestinal transit of pellets assessed by gamma scintigraphy using statistical moments.

Authors:  F Podczeck; J M Newton; K H Yuen
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

2.  Use of gamma distributed residence times in pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  In vitro--in vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example.

Authors:  D Brockmeier; H J Dengler; D Voegele
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.